A 7-week double-blind RCT found aripiprazole caused significantly less weight gain than risperidone in schizophrenia, with appetite changes as an early metabolic signal. PICO summary and expert commentary.
Author: Hormone Insight Editorial Team
Read More
A 453-patient non-inferiority trial found once-daily prolonged-release pregabalin worked about as well as immediate-release pregabalin for diabetic peripheral neuropathy, with both beating placebo. PICO summary and expert commentary.
A 93-patient Turkish RCT testing whether more frequent dietitian counseling, with weekly telehealth added, improves cardiometabolic outcomes in metabolic syndrome. PICO summary and expert commentary.
A randomized trial in 112 veterans found that immediate return of confirmed familial hypercholesterolemia genetic results plus telegenetic counseling did not significantly reduce LDL-C versus delayed return. PICO summary and expert commentary.
A new fellow on her first day, learning when to listen. A patient with eleven problems who, asked to pick one, picks sleep. Composite vignettes from a fictional teaching clinic.
A three-arm RCT shows 24 g/day dietary fibre improves HbA1c and the FIB-4 fibrosis marker in type 2 diabetes with MASLD. PICO summary and expert commentary for clinicians.
CARDS demonstrated that atorvastatin 10 mg reduces major cardiovascular events by 37% and stroke by 48% in patients with type 2 diabetes and normal to mildly elevated LDL-cholesterol without prior CVD, confirming that cardiovascular risk rather than LDL level should determine statin initiation and establishing universal statin use in primary cardiovascular prevention for type 2 diabetes.
HPS demonstrated that simvastatin reduces major vascular events by 24% across all high-risk patients regardless of baseline LDL-cholesterol level, including those with diabetes without established coronary disease, eliminating the treatment threshold concept and establishing absolute cardiovascular risk as the primary criterion for statin therapy — one of the most influential results in preventive cardiology.
WOSCOPS demonstrated that pravastatin reduces the combined incidence of nonfatal MI and coronary death by 31% in men with hypercholesterolaemia and no prior MI, establishing the primary prevention indication for statin therapy and providing the first large randomised evidence for population-level lipid lowering in high-risk individuals without established cardiovascular disease.
The 4S trial demonstrated that simvastatin reduces all-cause mortality by 30%, coronary death by 42%, and major coronary events by 34% in patients with established coronary heart disease and no excess non-cardiovascular mortality, resolving the safety debate and establishing statin therapy as the standard of care in secondary cardiovascular prevention.